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The Human Genome Project and the courts 
The courts will be called upon 
to settle an array of disputes 
involving genetic medicine among patients, 
health care professionals, insurers, 
and the government. 
' t)~f 
_J 
1 J. 
--,_,,~he impact of the Human 
Genome Project will be 
much broader than just 
making it possible to test 
people or to screen populations for 
genetic disorders. Gene thera-
pies-both in the form of drugs 
manufactured with genetic techno!-
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ogy and gene transfer involving the 
actual manipulation of cellular 
DNA-will usher in a new era of ge-
netic medicine. 
Gene therapy already is a reality. 
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Hundreds of clinical trials are un-
derway to test the safety and 
efficacy of gene therapy to treat dis-
orders such as cystic fibrosis and 
Parkinson's disease. 1 
So far, these new technologies are 
limited to producing so-called "so-
matic" effects in patients-that is, 
effects that do not alter reproduc-
This article was written under a grant from the 
Ethical, Legal, and Social Implications Research 
Program, Human Genome Research Institute, 
National Institutes of Health (No. I ROI 
HGOJ446-0IAI). The author thanks Senia 
Pickering for her exceptional research help. 
I. See McLachlan, Ho, Davidson-Smith, 
Sam ways, Davidson, Stevenson, Carothers, Alton, 
Middleton, Smith, Kallmeyer, Michaelis, Seeber, 
Naujoks, Greening, Innes, Dorin, and Porteou, 
LaboratOI)' and clinical studies in support of cystic ji-
&rosis gene therap_v using pCMV-CFTR-DOT:!P, 3 
GENE THER. lJ 13-1123 (1996); Colledge, Cystic fi-
brosis Gene Therapy, 4 CuR. OPIN. GENET. DEv. 466-
471 (1994); McElvaney, Is gene therapy in cystic fi-
brosis a realistit:-exfJectation?, 2 CuRR. 0PIN. Puu.I. 
MEO. 466-471 (!996). 
tive cells and therefore that would 
not be passed on to the patient's 
offspring. But studies have been 
proposed in which genetic manipu-
lations would change the DNA in-
side eggs or sperm. 2 These so-called 
2. Cooke, Pushing the Human Limit: Gene 
Therap_v That Could Affect Future Generations Too, 
NEwsow, August 3D, 1990, atA6. 
. 3. See Recombinant DNA Advisory Committee, 
Discussion Regarding the Use of Normal Sub-
jects m Human Gene Transfer Clinical Trials, 
lV!~rch 6_-7, 1997, pg. 2 (in author's possession) 
(dlscussmg protocol to characterize local, sys-
temic a':'d distant compartment immunity in nor-
malmdn~duals after intradermal administration 
?fa replication deficient AdS-based vector carry-
Ing gene coding for the E. coli enzyme, cytosine 
adenase). 
germ line gene therapies" intra-
duce the possibility of eliminating 
genetically-related diseases in suc-
ceeding generations. 
The future holds the prospect of 
even more da1ing genetic manipula-
tions. The Human Genome Project 
will provide scientists with the data 
and tools to identify and understand 
the basis of genetic diseases and dis-
orders, as well as other genetically-
related traits. This creates the pos-
sibility of genetic interventions to 
enhance non-disease traits, for ex-
ample, to increase strength, stamina, 
and perhaps even intelligence. Nor 
are these enhancement technologies 
just in the realm of science fiction. 
Scientists have begun to use gene 
transfer technologies to enhance the 
immune systems of advanced cancer 
and HIV-infected patients, and they 
are experimentally transferring "for-
eign" genes (i.e., not one's own) into 
healthy subjects in search of new 
mechanisms to deliver gene thera-
pies to patients.3 
These new technologies will create 
a host of difficult, often unprec-
edented, ethical and legal controver-
sies, many of which will find their way 
to the courts for resolution. 
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patients at risk for genetic ailments 
about the benefits and risks of new 
genetic technologies. Not only will 
they have to inform and advise pa-
tients about the complex matrix of 
individual genetic risk factors re-
vealed by an expanding array of ge-
netic tests, and to help patients com-
pare the medical benefits and risks of 
various gene therapies and alterna-
tive treatments; they also will be the 
primary source of patient informa-
tion about the non-medical costs of 
accessing genetic technologies, in-
cluding the risks of insurance and 
employment discrimination. 
Beyond gene therapy 
As mentioned at the outset of this ar-
ticle, the revolution in human genet-
ics will extend beyond identifying 
and preventing or treating genetic 
ailments. The same techniques that 
respond to genetic disorders also will 
be applicable to non-disease traits. 
Currently much work is underway to 
identify the proteins that genes 
"code for" in order to correct pro-
tein imbalances that produce illness. 
The same process can be used to pro-
duce drugs that affect any other pro-
tein-dependent characteristic, not 
just those that are regarded as ill-
nesses. Similarly, gene transfer tech-
nology that will be used to remove 
errant DNA or to install healthy DNA 
also will be able to manipulate DNA 
for other purposes. 
At this point it is not known how 
many non-disease human character-
istics are, at least in part, inherited. 
But research already has confirmed 
that certain traits that many would 
consider fundamental to personal 
well-being and social success-traits 
such as beauty, strength, and intelli-
gence-are substantially influenced 
by a person's genetic endowmentY 
Many of these traits probably are 
"multifactorial"-that is, the result 
of the interaction of numerous indi-
vidual genes and with environmental 
factors. Altering the function of one 
of these genes may have undesired ef-
fects on other physical or mental 
characteristics. Eventually, however, 
research is likely to reveal techniques 
for successfully "improving" or "en-
Research is likely to reveal techniques for successfully "improving" or 
"enhancing" non-genetic traits such as strength or beauty. 
hancing" a person's non-disease ge-
netic traits. This raises a host of prob-
lems that will begin to confront the 
judicial system in the next century. I 
want to discuss a few of the most chal-
lenging issues here. 
Parental authority 
It is a truism that parents typically 
want to give their children the best 
chance in life that they can. Indeed, 
some parents seem to know no 
bounds, such as the mother who was 
sentenced to 10 years in jail for plot-
ting to murder a popular junior high 
school cheerleader so that her 
daughter could fill the vacancy on 
the cheerleading squad. 14 
Parents not only put their children 
in private schools and pay for piano 
lessons; increasingly they turn to 
medical interventions to give their 
kids a perceived advantage over oth-
ers. An endocrinologist reports being 
asked by parents to prescribe human 
growth hormone to their child so 
that she could gain the two inches in 
13. See, e.g., Bouchard, Genes, Environment, and 
Personality, 264 SciENCE 1700 (1994) (stating that 
"two-thirds of the reliable variance in measured 
personality traits is due to genetic influence"). 
See also Finkel et. al., Heritability of Cognitive Abili-
ties in Adult Twins: Comparison of lvlinnesota and 
Swedish Data, 25 BEHAVIOR GENETICS 421, 430 
(1995) (estimating that cognition in early and 
middle adulthood has a heritability factor of ap-
proximately 81%); Petri!! et. al., The Geneti:ccztnd-
Environmental Variance Underlying ElementaT)• Cog-
nitive Tasks, 25 BEHAVIOR GENETICS 199 (i995) 
height needed to make her an irre-
sistible candidate for college volley-
ball scholarships. 15 A recent report in 
the press says that a growing number 
of parents in California and other 
Sun belt states are giving their daugh-
ters breast implants as high school 
graduation presents. 16 
The question that the courts will 
be forced to struggle with is whether 
there is a legal limit to the authority 
of parents to manipulate the genetic 
characteristics of their children. One 
way this issue will arise is when par-
ents give their children drugs to im-
prove performance in sports compe-
titions or mental achievement tests. 
Even if these practices are not ex-
pressly forbidden by law or by the pri-
vate legal rules governing the activity, 
the possible health risks may subject 
parents to charges of child endanger-
ment. Similar doubts about parental 
fitness would arise if parents agreed 
to let their children participate in ex-
periments to determine the safety 
and efficacy of enhancement prod-
(demonstrating that elementary cognitive tasks 
display genetic effects). 
14. See, C/zeerleade·r Case Sentence, N.Y. Times, 
Sept. 10, 1996, at A23 ("[a] woman who offered 
her diamond earrings in a murder-for-hire plot 
aimed at getting her daughter on the junior high 
cheerleading squad was sentenced to 10 years in 
prison today"). 
15. Personal communication from Thomas H. 
Murray, President, The Hastings Center. 
16. Cleveland Plain Dealer, April 23, 1999, at 
19-A. 
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ucts. In none of these cases, more-
over, would the parents be able to 
hide behind the shield of religious 
freedom, as they often can now in 
making questionable treatment deci-
sions for their children. 17 
Yet parents are not likely to wait 
until a child is born in order to at-
tempt to influence its genetic inherit-
ance, including its inheritance of 
non-disease characteristics. The avail-
ability of genetic tests will open the 
door to several types of genetic en-
hancements that will take place 
much earlier. The first of these is pre-
conception enhancement, in which deci-
sions about whether or not and with 
whom to conceive a child 
would be made on the ba-
sis of pre-conception ge-
netic testing. Just as some 
people now test them-
diseases. An alternative to selective 
abortion would be emln~'I'Q.selection for 
enhancement, which combines genetic 
testing with in vitro fertilization so 
that embryos were tested before they 
were implanted in the womb, and 
only embryos with advantageous 
characteristics were implanted. 
Finally, and most dramatically, an 
early-stage embryo might be geneti-
cally altered prior to implantation, 
with DNA inserted or deleted to pro-
duce desired traits in the resulting 
child. If performed at an early-
enough stage of embryonic develop-
ment, the alteration would affect all 
subsequent fetal cells, including 
Those who can afford 
poses, even though parents have a 
constitutional right to abort and per-
haps even to select embryos for im-
plantation when they do so for medi-
cal reasons, such as to avoid the birth 
of a child with a genetic illness. 18 
An interesting question is what the 
state's interest would be in regulating 
parental access to genetic enhance-
ment for their children. The interest 
might be the need to prevent harm 
to the future child, similar to the jus-
tification offered for government ac-
tions to prohibit illegal drug use by 
pregnant women that threatens the 
health of the fetus. Yet assuming that 
genetic enhancement techniques are 
developed that do not 
physically harm the child, 
the state would have to 
selves to avoid conceiving 
a child with another per-
son who is a "carrier" for 
a recessive genetic disor-
der, prospective mates in 
the future could test 
themselves to ascertain if 
to purchase genetic 
enhancements v,rill gain 
significant social advantages. 
rely on less tangible forms 
of harm. Some commen-
tators have suggested that 
genetic enhancement in-
terferes with the child's 
right to genetic au-
tonomy-that children 
deserve a genetic endow-
ment free from parental 
manipulation. 19 Yet par-they were likely to pro-
duce offspring who were "superior" 
in terms of non-disease characteris-
tics. Unsatisfactory results would lead 
to decisions not to marry or not to 
conceive, at least not without employ-
ing genetic manipulations to im-
prove the genetic profile of the off-
spring. 
Another form of genetic enhance-
ment stemming from genetic testing 
would be enhancement via selective abor-
tion. Fetuses would be tested in utero 
and those that did not match up to 
parents' expectations would be 
aborted, just as fetuses currently 
might be aborted if they tested posi-
tive for abnormalities or incurable 
17. See, e.g., Massie, The Religion Clauses and Pa· 
rental Health Care Decision making for Children: Sug· 
gestions for a New Approach, 21 HAsTINGS CoNSTL. L. 
Q. 725 (1994). 
18. See, e.g., Malinowski, Coming Into Being: 
Law, Ethics, and the Practice of Prenatal Genetic 
Screening, 45 HASTINGS L.j. 1435, 1450 (1994). 
Cited in Robertson, Genetic Selection of Offspring 
Characteristics, 76 B.U. L. REv. 421 (1996). 
19. See generally Agar, Designing Babies: Morally 
Permissible Ways to j\!Jodi./)' the Human Genome, 9 
BIOETHICs 1·15 (1995); Elliot, Identity and the Ethics 
of Gene Therapy, 7 BIOETHJCS 27-40 (1993); Kahn, 
germ cells-that is, those that became 
eggs or sperm. This would result in 
germ-cell enhancement, in which genetic 
changes would be passed on when the 
enhanced individual reproduced. 
Some of these actions undoubtedly 
lie within the realm of constitution-
ally protected personal autonomy 
and reproductive freedom, for ex-
ample, the decision about whom to 
marry based on genetic testing. 
Other activities may not be so clearly 
protected. Some scholars argue, for 
example, that the state has a legiti-
mate interest in regulating selective 
abortion and embryo selection when 
performed for enhancement pur-
Genetic Harm: Bitten by the Body that Keeps You?, 5 
BWETHICS 289-309 ( 1991); Persoson, Genetic 
Therapy, Identity and the Person-Regarding Reasons, 9 
BIOETHJCS 18-31 (1995); Zohar, Prospects for "Gene 
Therapy "-Can a Person Benefit from Being Altered?, 
5 BJOETHICS 275-288 (1991); Dwyer, Parents' Reli· 
gion and Children's Welfare: Debunking the Doctrine 
of Parents' Rights, 82 CAL. L. REv. 1371, 1446-1447 
(1994), Cited in Robertson, supra n. 18. 
20. For a fuller discussion of wealth-based ac· 
cess to genetic enhancement, see Mehlman and 
Botkin, ACCESS TO THE GENOME: THE CHALLENGE TO 
EQUALITY (Georgetown University Press, 1999). 
ents invariably manipulate their 
children's futures once they are 
born. What is so different about do-
ing so before the child is born, as-
suming that the manipulation is ben-
eficial to the child? 
A stronger basis for upholding gov-
ernmental restrictions on parents' 
ability genetically to enhance their 
children might be the negative im-
pact of genetic enhancement on our 
democratic political system. Genetic 
enhancement is likely to be acces-
sible only to wealthier families, since 
it is not likely to be covered by public 
or private health insurance plans.20 
Assuming that genetic enhance-
ment is effective at improving per-
sonal traits that correlate with social 
success, those who can afford to pur-
chase genetic enhancements will 
gain significant social advantages, 
and the ability to genetically enhance 
their children, particularly the use of 
germ line enhancements that are 
passed on to succeeding generations, 
could create a "genobility" with an 
unassailable lock on power and privi-
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lege. The threat that this poses is 
more than just a philosophical objec-
tion to social inequality; it is a threat 
to the fundamental belief in equality 
of opportunity that sustains our po-
litical system in the face of frank dis-
parities of wealth, privilege, and 
power. If, as the result of wealth~ 
based access to genetic enhance-
ment, society becomes divided into 
genetic haves (the enhanced) and 
have no ts (the unenhanced), the 
possibility of upward social mobility 
will be seen as illusory. In the face of 
such a hardened class structure, the 
underclass is likely to rebel, in turn 
provoking anti-democratic repres-
sion by the genetic upper class. Even 
if a stable political system eventually 
emerged, it would not resemble 
Western liberal democracy. 
Avoiding such a fate is a sufficiently 
compelling state interest to justify a 
wide range of restrictions on parental 
enhancement of offspring, as well as 
substantial limitations on the free-
dom of adults to purchase enhance-
ments for themselves. For example, 
the law might legitimately ban the 
use of germ line genetic enhance-
ments, and it might allow persons to 
purchase somatic enhancements for 
themselves only on condition that 
they make an enforceable commit-
ment to employ their advantages 
for social and not just personal 
benefit, in much the same way that 
we license professionals such as 
doctors and lawyers.~ 1 
Unfairness 
No matter what approach society 
takes to genetic enhancements, some 
individuals undoubtedly will obtain 
them-whether by becoming li-
censed or by purchasing them in an 
unregulated free market or through 
black or gray markets in a highly re-
stricted system of access. These indi-
viduals will gain significant advan-
tages over unenhanced persons with 
whom they interact or compete. How 
should the law respond to the poten-
tial unfairness of these interactions? 
The law is no stranger to imbal-
ances between interacting parties. In 
certain situations, courts are called 
upon to enforce bans on such interac-
tions, such as the private rules that 
prohibit the use of performance-en-
har1Cing drugs in the Olympics or 
other sports competitions, or the se-
curities laws that ban trading on in-
side information. In other situations, 
the law requires the advantaged party 
to disgorge the advantage to the ben-
efit of the other party, such as by re-
quiring disclosure of information to 
correct a material mistake by the 
other party to a contract negotia-
tion. 22 The doctrine of unconsciona-
bility allows courts to void a contract if 
the outcome, resulting from an im-
balance of market power or informa-
tion between the parties, seems too 
unfair. 23 In still other contexts, the law 
eliminates the arm's length nature of 
the transaction, making the advan-
taged party a fiduciary who must act 
in the other party's best interests. 2 ~ 
Yet in some instances, the rules seem 
blind to the potential unfairness. SAT 
scores for college applicants are not 
weighted in terms of IQ, despite the 
obvious unfairness. Shorter basket-
ball players are not allowed to shoot 
from stepladders. 
These varying responses of the law 
make it difficult to predict how 
courts will respond to the unfairness 
created by genetic enhancements. 
Yet it seems certain that, at least in 
some cases, courts will feel com-
pelled to level the playing field. 
Negligence 
A final illustration of the potential 
impact of genetic enhancement on 
the courts is its effect on the standard 
of care to which people are expected 
to adhere when they create risks of 
injury to one another. Should an en-
hanced person be held to the stan-
dard of care of an ordinary reason-
able person, or to the standard of an 
enhanced person? An obvious an-
swer might be that, if enhanced per-
sons ought to be better at avoiding 
accidents than unenhanced persons, 
then the enhanced persons should 
be held to an enhanced person's 
standard of care. In other words, they 
should not escape liability by showing 
that they met a reasonable person's 
standard of care when, by virtue of 
their enhancements, they ought to 
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have done better. 
Automobile drivers with enhanced 
vision who run over children, for ex-
ample, should not be heard to argue 
that, although they could have seen 
the child in enough time to stop, they 
were not negligent since an ordinary 
person would not have been able to 
stop in time. This seems to be the an-
swer that the Restatement of Torts 
would give, since section 289 states 
that, at least in regard to appreciating 
the risk created by one's behavior, an 
actor must use "such superior atten-
tion, perception, memory, knowl-
edge, intelligence, and judgment as 
the actor himself has." 
A good argument can be made, 
however, that when it comes to reduc-
ing the costs of accidents, we indeed 
ought to hold an enhanced person to 
the lower standard of an ordinary 
"reasonable" person. The reason is 
that by not penalizing them with an 
enhanced person's standard, we will 
encourage more people to enhance 
themselves, thereby reducing acci-
dents simply because, as a result of 
their better vision or reflexes or intel-
ligence, enhanced people are better 
at avoiding them. 
A different society 
The broad scope of the issues men-
tioned in this article-from automo-
bile accidents to altering the genes of 
future generations-demonstrates 
the breadth of the impact that gene 
therapy and related technologies will 
have on our society. They will chal-
lenge conventional notions of illness, 
insurance, personal worth, and de-
sert, and the limits of governmental 
control over individual freedom and 
parental discretion. Ultimately the 
courts will decide how far the law can 
go in response to these challenges. 
One thing is certain: the society that 
emerges will look very different from 
our own. ~14) 
21. For a more complete discussion of these so-
cietal responses, see Mehlman, The Law of r1bove 
Averages: Leveling the New Genetic Enhancement Play-
ing Field, IowAL. REv. (forthcoming). 
22. See RESTATEMENT (SECOND) OF CONTRACTS 
§161 (d) (1981). 
23. See RESTATEMENT (SECOND) OF CONTRACTS 
§153 (1981). 
24. See REsTATEMENT (SECOND) OF TRUSTS §170 
(1957). 
